Mirati Therapeutics, Inc. Banner Image

Mirati Therapeutics, Inc.

  • Ticker MRTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Mirati Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in San Diego, California
Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of products targeting oncology. Its clinical stage product candidates include MGCD265, a multi-targeted kinase inhibitor that is in Phase 1b clinical development trials for the treatment of solid tumors indications, including lung, head and neck, and gastric cancers; MGCD516, a kinase inhibitor, whichMore is in Phase 1 clinical development for the treatment of patients with non-small cell lung cancer and solid tumors; and Mocetinostat, an orally-bioavailable histone deacetylase inhibitor that is in Phase 2 clinical trial development for patients with bladder cancer, myelodysplastic syndrome, and non-hodgkins lymphoma, principally diffuse large B-cell lymphoma and follicular lymphoma. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Mirati Therapeutics, Inc.

Most Recent Annual Report

Mirati Therapeutics, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Mirati Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports